Loading…
Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C
Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently suffer fr...
Saved in:
Published in: | Yonsei medical journal 2013, 54(6), , pp.1545-1549 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1549 |
container_issue | 6 |
container_start_page | 1545 |
container_title | Yonsei medical journal |
container_volume | 54 |
creator | Lee, Mi-Na Woo, Hye In Lee, Yoo Min Kang, Ben Kim, Jong-Won Choe, Yon Ho Lee, Soo-Youn |
description | Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently suffer from severe myelosuppression. Here, we report a patient with TPMT*3C/*3C who managed successfully with monitoring of thiopurine metabolites. The patient was an 18-year-old male diagnosed with Crohn's disease. The standard dose of azathioprine (AZA) (1.8 mg/kg/day) with mesalazine (55.6 mg/kg/day) was prescribed. Two weeks after starting AZA treatment, the patient developed leukopenia. The DNA sequence analysis of TPMT identified a homozygous missense variation (NM_000367.2: c.719A>G; p.Tyr240Cys), TPMT*3C/*3C. He was treated with adjusted doses of azathioprine (0.1-0.2 mg/kg/day) and his metabolites were closely monitored. Leukopenia did not reoccur during the follow-up period of 24 months. To our knowledge, this is the first case of a patient homozygous for TPMT*3C successfully treated with azathioprine in Korea. While a TPMT genotyping test may be helpful to determine a safe starting dose, it may not completely prevent myelosuppression. Monitoring metabolites as well as routine laboratory tests can contribute to assessing drug metabolism and optimizing drug dosing with minimized drug-induced toxicity. |
doi_str_mv | 10.3349/ymj.2013.54.6.1545 |
format | article |
fullrecord | <record><control><sourceid>pubmed_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_331424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24142665</sourcerecordid><originalsourceid>FETCH-LOGICAL-n299t-2b28ca913564a10dca5d1dab9c1b7b0bd4d1146b8861a04a468c31b5f1f9bc183</originalsourceid><addsrcrecordid>eNpVkMtu1DAUhi0EosPAC7BAXrJJ8PEt8QapGhWoVASCYR0dO86M2zgeJR6q6ZoHx7SAYPXr6L_o6CPkJbBaCGnenOJ1zRmIWsla16CkekRWYBpdcSmax2TFFIhKNUafkWfLcs0Yb4Dxp-SMS5Bca7UiP74enfPLMhxHineY9yEd5jB5mmePOfop09uQ9zT6jDaNIXsa0xRyKqEdDRNFevB9wDwHV85hxBixuCdq060faR8Wj4unB8zh19g-xXR32qXjQoc00-3nj1uxeU6eDDgu_sVvXZNv7y62mw_V1af3l5vzq2rixuSKW946NCCUlgisd6h66NEaB7axzPayB5Datq0GZBKlbp0AqwYYjHXQijV5_bA7zUN340KXMNzrLnU3c3f-ZXvZCVHQyBJ9-xA9HG30vSu_zzh2hU3E-XRf_N-Zwr7MfO9Ey0xbuK_Jq38H_jb_oBc_AXCvi68</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C</title><source>Open Access: PubMed Central</source><creator>Lee, Mi-Na ; Woo, Hye In ; Lee, Yoo Min ; Kang, Ben ; Kim, Jong-Won ; Choe, Yon Ho ; Lee, Soo-Youn</creator><creatorcontrib>Lee, Mi-Na ; Woo, Hye In ; Lee, Yoo Min ; Kang, Ben ; Kim, Jong-Won ; Choe, Yon Ho ; Lee, Soo-Youn</creatorcontrib><description>Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently suffer from severe myelosuppression. Here, we report a patient with TPMT*3C/*3C who managed successfully with monitoring of thiopurine metabolites. The patient was an 18-year-old male diagnosed with Crohn's disease. The standard dose of azathioprine (AZA) (1.8 mg/kg/day) with mesalazine (55.6 mg/kg/day) was prescribed. Two weeks after starting AZA treatment, the patient developed leukopenia. The DNA sequence analysis of TPMT identified a homozygous missense variation (NM_000367.2: c.719A>G; p.Tyr240Cys), TPMT*3C/*3C. He was treated with adjusted doses of azathioprine (0.1-0.2 mg/kg/day) and his metabolites were closely monitored. Leukopenia did not reoccur during the follow-up period of 24 months. To our knowledge, this is the first case of a patient homozygous for TPMT*3C successfully treated with azathioprine in Korea. While a TPMT genotyping test may be helpful to determine a safe starting dose, it may not completely prevent myelosuppression. Monitoring metabolites as well as routine laboratory tests can contribute to assessing drug metabolism and optimizing drug dosing with minimized drug-induced toxicity.</description><identifier>ISSN: 0513-5796</identifier><identifier>EISSN: 1976-2437</identifier><identifier>DOI: 10.3349/ymj.2013.54.6.1545</identifier><identifier>PMID: 24142665</identifier><language>eng</language><publisher>Korea (South): Yonsei University College of Medicine</publisher><subject>Adolescent ; Azathioprine - adverse effects ; Azathioprine - therapeutic use ; Case Report ; Homozygote ; Humans ; Inflammatory Bowel Diseases - drug therapy ; Inflammatory Bowel Diseases - enzymology ; Inflammatory Bowel Diseases - genetics ; Inflammatory Bowel Diseases - metabolism ; Male ; Methyltransferases - genetics ; 의학일반</subject><ispartof>Yonsei Medical Journal, 2013, 54(6), , pp.1545-1549</ispartof><rights>Copyright: Yonsei University College of Medicine 2013 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809851/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809851/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24142665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001814087$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Mi-Na</creatorcontrib><creatorcontrib>Woo, Hye In</creatorcontrib><creatorcontrib>Lee, Yoo Min</creatorcontrib><creatorcontrib>Kang, Ben</creatorcontrib><creatorcontrib>Kim, Jong-Won</creatorcontrib><creatorcontrib>Choe, Yon Ho</creatorcontrib><creatorcontrib>Lee, Soo-Youn</creatorcontrib><title>Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C</title><title>Yonsei medical journal</title><addtitle>Yonsei Med J</addtitle><description>Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently suffer from severe myelosuppression. Here, we report a patient with TPMT*3C/*3C who managed successfully with monitoring of thiopurine metabolites. The patient was an 18-year-old male diagnosed with Crohn's disease. The standard dose of azathioprine (AZA) (1.8 mg/kg/day) with mesalazine (55.6 mg/kg/day) was prescribed. Two weeks after starting AZA treatment, the patient developed leukopenia. The DNA sequence analysis of TPMT identified a homozygous missense variation (NM_000367.2: c.719A>G; p.Tyr240Cys), TPMT*3C/*3C. He was treated with adjusted doses of azathioprine (0.1-0.2 mg/kg/day) and his metabolites were closely monitored. Leukopenia did not reoccur during the follow-up period of 24 months. To our knowledge, this is the first case of a patient homozygous for TPMT*3C successfully treated with azathioprine in Korea. While a TPMT genotyping test may be helpful to determine a safe starting dose, it may not completely prevent myelosuppression. Monitoring metabolites as well as routine laboratory tests can contribute to assessing drug metabolism and optimizing drug dosing with minimized drug-induced toxicity.</description><subject>Adolescent</subject><subject>Azathioprine - adverse effects</subject><subject>Azathioprine - therapeutic use</subject><subject>Case Report</subject><subject>Homozygote</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Inflammatory Bowel Diseases - enzymology</subject><subject>Inflammatory Bowel Diseases - genetics</subject><subject>Inflammatory Bowel Diseases - metabolism</subject><subject>Male</subject><subject>Methyltransferases - genetics</subject><subject>의학일반</subject><issn>0513-5796</issn><issn>1976-2437</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkMtu1DAUhi0EosPAC7BAXrJJ8PEt8QapGhWoVASCYR0dO86M2zgeJR6q6ZoHx7SAYPXr6L_o6CPkJbBaCGnenOJ1zRmIWsla16CkekRWYBpdcSmax2TFFIhKNUafkWfLcs0Yb4Dxp-SMS5Bca7UiP74enfPLMhxHineY9yEd5jB5mmePOfop09uQ9zT6jDaNIXsa0xRyKqEdDRNFevB9wDwHV85hxBixuCdq060faR8Wj4unB8zh19g-xXR32qXjQoc00-3nj1uxeU6eDDgu_sVvXZNv7y62mw_V1af3l5vzq2rixuSKW946NCCUlgisd6h66NEaB7axzPayB5Datq0GZBKlbp0AqwYYjHXQijV5_bA7zUN340KXMNzrLnU3c3f-ZXvZCVHQyBJ9-xA9HG30vSu_zzh2hU3E-XRf_N-Zwr7MfO9Ey0xbuK_Jq38H_jb_oBc_AXCvi68</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Lee, Mi-Na</creator><creator>Woo, Hye In</creator><creator>Lee, Yoo Min</creator><creator>Kang, Ben</creator><creator>Kim, Jong-Won</creator><creator>Choe, Yon Ho</creator><creator>Lee, Soo-Youn</creator><general>Yonsei University College of Medicine</general><general>연세대학교의과대학</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope><scope>ACYCR</scope></search><sort><creationdate>20131101</creationdate><title>Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C</title><author>Lee, Mi-Na ; Woo, Hye In ; Lee, Yoo Min ; Kang, Ben ; Kim, Jong-Won ; Choe, Yon Ho ; Lee, Soo-Youn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-n299t-2b28ca913564a10dca5d1dab9c1b7b0bd4d1146b8861a04a468c31b5f1f9bc183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Azathioprine - adverse effects</topic><topic>Azathioprine - therapeutic use</topic><topic>Case Report</topic><topic>Homozygote</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Inflammatory Bowel Diseases - enzymology</topic><topic>Inflammatory Bowel Diseases - genetics</topic><topic>Inflammatory Bowel Diseases - metabolism</topic><topic>Male</topic><topic>Methyltransferases - genetics</topic><topic>의학일반</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Mi-Na</creatorcontrib><creatorcontrib>Woo, Hye In</creatorcontrib><creatorcontrib>Lee, Yoo Min</creatorcontrib><creatorcontrib>Kang, Ben</creatorcontrib><creatorcontrib>Kim, Jong-Won</creatorcontrib><creatorcontrib>Choe, Yon Ho</creatorcontrib><creatorcontrib>Lee, Soo-Youn</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Yonsei medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Mi-Na</au><au>Woo, Hye In</au><au>Lee, Yoo Min</au><au>Kang, Ben</au><au>Kim, Jong-Won</au><au>Choe, Yon Ho</au><au>Lee, Soo-Youn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C</atitle><jtitle>Yonsei medical journal</jtitle><addtitle>Yonsei Med J</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>54</volume><issue>6</issue><spage>1545</spage><epage>1549</epage><pages>1545-1549</pages><issn>0513-5796</issn><eissn>1976-2437</eissn><abstract>Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently suffer from severe myelosuppression. Here, we report a patient with TPMT*3C/*3C who managed successfully with monitoring of thiopurine metabolites. The patient was an 18-year-old male diagnosed with Crohn's disease. The standard dose of azathioprine (AZA) (1.8 mg/kg/day) with mesalazine (55.6 mg/kg/day) was prescribed. Two weeks after starting AZA treatment, the patient developed leukopenia. The DNA sequence analysis of TPMT identified a homozygous missense variation (NM_000367.2: c.719A>G; p.Tyr240Cys), TPMT*3C/*3C. He was treated with adjusted doses of azathioprine (0.1-0.2 mg/kg/day) and his metabolites were closely monitored. Leukopenia did not reoccur during the follow-up period of 24 months. To our knowledge, this is the first case of a patient homozygous for TPMT*3C successfully treated with azathioprine in Korea. While a TPMT genotyping test may be helpful to determine a safe starting dose, it may not completely prevent myelosuppression. Monitoring metabolites as well as routine laboratory tests can contribute to assessing drug metabolism and optimizing drug dosing with minimized drug-induced toxicity.</abstract><cop>Korea (South)</cop><pub>Yonsei University College of Medicine</pub><pmid>24142665</pmid><doi>10.3349/ymj.2013.54.6.1545</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0513-5796 |
ispartof | Yonsei Medical Journal, 2013, 54(6), , pp.1545-1549 |
issn | 0513-5796 1976-2437 |
language | eng |
recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_331424 |
source | Open Access: PubMed Central |
subjects | Adolescent Azathioprine - adverse effects Azathioprine - therapeutic use Case Report Homozygote Humans Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - enzymology Inflammatory Bowel Diseases - genetics Inflammatory Bowel Diseases - metabolism Male Methyltransferases - genetics 의학일반 |
title | Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT3C |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A22%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20azathioprine%20treatment%20with%20metabolite%20monitoring%20in%20a%20pediatric%20inflammatory%20bowel%20disease%20patient%20homozygous%20for%20TPMT3C&rft.jtitle=Yonsei%20medical%20journal&rft.au=Lee,%20Mi-Na&rft.date=2013-11-01&rft.volume=54&rft.issue=6&rft.spage=1545&rft.epage=1549&rft.pages=1545-1549&rft.issn=0513-5796&rft.eissn=1976-2437&rft_id=info:doi/10.3349/ymj.2013.54.6.1545&rft_dat=%3Cpubmed_nrf_k%3E24142665%3C/pubmed_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-n299t-2b28ca913564a10dca5d1dab9c1b7b0bd4d1146b8861a04a468c31b5f1f9bc183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24142665&rfr_iscdi=true |